Company research
Tempus AI, Inc.
CIK 1717115Updated Nov 3, 2026
SecurityTEM · NASDAQ · equity
Name history
Tempus Labs, Inc. · through Dec 5, 2023
TEM price & chart
Loading TradingView…
NASDAQ:TEM on TradingView ↗About the company
Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus
In the news
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed ↗
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus ↗
The Future of Intoxication Detection May Be in Your Voice ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
4 filing
SCHEDULE 13G/A - filed by KEYWELL BRADLEY A regarding Tempus AI, Inc.
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 2,281,424,000Source | 971,728,000Source | 2,365,911,000Source | 1,625,365,000Source | 864,611,000Source | 2,135,091,000Source | 1,543,137,000Source | — | 2,274,838,000Source | 926,116,000Source | 564,052,000Source |
| Property, Plant and Equipment, NetUSD | 90,710,000Source | 59,392,000Source | 89,066,000Source | 92,563,000Source | 60,539,000Source | 88,593,000Source | 93,536,000Source | — | 89,156,000Source | 58,056,000Source | 61,681,000Source |
| GoodwillUSD | 465,140,000Source | 73,365,000Source | 470,166,000Source | 325,793,000Source | 73,345,000Source | 470,169,000Source | 325,774,000Source | — | 470,211,000Source | 73,343,000Source | 73,354,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 372,876,000Source | 14,289,000Source | 312,457,000Source | 387,564,000Source | 16,252,000Source | 330,587,000Source | 399,544,000Source | — | 355,253,000Source | 11,716,000Source | 21,916,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 655,918,000Source | 388,006,000Source | 599,614,000Source | 186,310,000Source | 478,811,000Source | 521,170,000Source | 151,603,000Source | 79,942,000Source | 604,787,000Source | 340,954,000Source | 165,767,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 283,626,000Source | 145,616,000Source | 360,924,000Source | 266,284,000Source | 118,106,000Source | 308,599,000Source | 262,613,000Source | — | 311,170,000Source | 154,819,000Source | 94,462,000Source |
| Inventory, NetUSD | 54,976,000Source | 36,138,000Source | 53,512,000Source | 47,600,000Source | 32,690,000Source | 51,831,000Source | 50,485,000Source | — | 51,724,000Source | 38,386,000Source | 28,845,000Source |
| Assets, CurrentUSD | 1,146,511,000Source | 679,412,000Source | 1,290,865,000Source | 644,201,000Source | 671,366,000Source | 1,053,942,000Source | 573,970,000Source | — | 1,167,175,000Source | 667,603,000Source | 350,331,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 42,611,000Source | 31,335,000Source | 42,938,000Source | 36,476,000Source | 29,704,000Source | 42,530,000Source | 42,086,000Source | — | 40,498,000Source | 26,135,000Source | 17,295,000Source |
| Operating Lease, Right-of-Use AssetUSD | 66,901,000Source | 14,141,000Source | 60,553,000Source | 38,651,000Source | 13,994,000Source | 62,306,000Source | 39,626,000Source | — | 64,496,000Source | 14,762,000Source | 20,530,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 1,773,600,000Source | 918,000,000Source | 1,920,977,000Source | 1,315,803,000Source | 766,360,000Source | 1,718,686,000Source | 1,216,943,000Source | — | 1,783,512,000Source | 869,777,000Source | 840,672,000Source |
| Stockholders’ equity: | |||||||||||
| Retained Earnings (Accumulated Deficit)USD | -2,341,696,000Source | -2,137,820,000Source | -2,516,139,000Source | -2,261,714,000Source | -2,061,980,000Source | -2,521,781,000Source | -2,218,871,000Source | — | -2,395,862,000Source | -2,150,834,000Source | -1,396,917,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,533,000Source | 10,208,000Source | -1,941,000Source | 8,448,000Source | -94,000Source | -908,000Source | 4,692,000Source | — | 902,000Source | 94,000Source | 5,000Source |
| Stockholders' Equity Attributable to ParentUSD | 507,824,000Source | 53,728,000Source | 444,934,000Source | 309,562,000Source | 98,251,000Source | 416,405,000Source | 326,194,000Source | -1,474,425,000Source | 491,326,000Source | 56,339,000Source | -1,382,163,000Source |
| Additional Paid in Capital, Common StockUSD | 2,847,571,000Source | 2,184,926,000Source | 2,969,637,000Source | 2,566,412,000Source | 2,163,911,000Source | 2,945,718,000Source | 2,543,957,000Source | — | 2,892,910,000Source | 2,210,664,000Source | 18,345,000Source |
| Liabilities and EquityUSD | 2,281,424,000Source | 971,728,000Source | 2,365,911,000Source | 1,625,365,000Source | 864,611,000Source | 2,135,091,000Source | 1,543,137,000Source | — | 2,274,838,000Source | 926,116,000Source | 564,052,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 350,028,000Source | 252,620,000Source | 391,492,000Source | 418,160,000Source | 181,564,000Source | 317,956,000Source | 336,470,000Source | — | 372,388,000Source | 291,070,000Source | 232,627,000Source |
| Operating Lease, Liability, CurrentUSD | 12,417,000Source | 5,894,000Source | 12,192,000Source | 9,381,000Source | 5,828,000Source | 12,639,000Source | 9,420,000Source | — | 13,355,000Source | 6,459,000Source | 6,437,000Source |
| Accounts Payable, CurrentUSD | 59,553,000Source | 49,027,000Source | 73,818,000Source | 79,323,000Source | 28,646,000Source | 41,023,000Source | 88,732,000Source | — | 81,994,000Source | 53,804,000Source | 54,421,000Source |
| Operating Lease, Liability, NoncurrentUSD | 77,723,000Source | 26,664,000Source | 71,266,000Source | 45,866,000Source | 27,238,000Source | 72,723,000Source | 47,567,000Source | — | 74,272,000Source | 26,199,000Source | 32,040,000Source |
| Other Liabilities, NoncurrentUSD | 58,772,000Source | 15,403,000Source | 56,270,000Source | 9,508,000Source | 16,790,000Source | 54,115,000Source | 9,670,000Source | — | 56,600,000Source | 15,980,000Source | 19,751,000Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | 160,773,000Source | 101,985,000Source | 181,271,000Source | 165,903,000Source | 85,185,000Source | 160,628,000Source | 129,238,000Source | — | 155,370,000Source | 130,407,000Source | 82,517,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 330,000Source | 234,000Source | 123,000Source |
| Dividends Payable, CurrentUSD | — | 0Source | — | — | 0Source | — | — | — | — | 0Source | 9,797,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 52,706,000Source | 22,974,000Source | 124,747,000Source | 534,138,000Source | 0Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,990,000Source | 45,175,000Source | 90,402,000Source | 61,037,000Source | 7,347,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 332,000Source | 911,000Source | 3,369,000Source | 9,541,000Source | 6,563,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -50,553,000Source | 23,572,000Source | -7,241,000Source | -23,852,000Source | -23,363,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | -46,216,000Source | -52,665,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -73,277,000Source | -105,624,000Source | -218,090,000Source | -189,045,000Source | -214,339,000Source |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | 0Source | 380,762,000Source | 376,666,000Source | 0Source | 5,705,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -10,067,000Source | -375,818,000Source | -398,355,000Source | -130,392,000Source | -40,313,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 8,202,000Source | 2,074,000Source | 21,049,000Source | 22,121,000Source | 34,608,000Source |
| Cash flows from financing activities: | |||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 69,918,000Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -271,000Source | 293,042,000Source | 884,123,000Source | 494,329,000Source | 117,547,000Source |
| Dividends paid | — | — | — | — | — | — | — | — | —Source | —Source | —Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 276,892,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -83,587,000Source | -188,509,000Source | 267,616,000Source | 175,228,000Source | -137,124,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 660,549,000Source | 388,878,000Source | 604,338,000Source | 188,051,000Source | 525,864,000Source | 153,326,000Source | 609,451,000Source | 341,835,000Source | 166,607,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 9,322,000Source | 10,849,000Source | 44,031,000Source | 28,045,000Source | 16,913,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -56,000Source | 0Source | 654,000Source | 206,000Source | 161,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 28,000Source | -109,000Source | -62,000Source | 336,000Source | -19,000Source |
| Additional Financial Items | |||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | 57,000Source | 248,000Source | 268,000Source | 197,000Source | 90,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 33,979,000Source | 21,038,000Source | 54,121,000Source | 22,455,000Source | 52,706,000Source | 22,974,000Source | 124,747,000Source | 534,138,000Source | 0Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 86,000Source | 157,000Source | 484,000Source | 510,000Source | 510,000Source |
| DepreciationUSD | — | — | 8,120,000Source | 6,788,000Source | 7,125,000Source | 8,347,000Source | 7,425,000Source | 7,883,000Source | 32,054,000Source | 26,356,000Source | 21,279,000Source |
| Depreciation, NonproductionUSD | — | — | 4,036,000Source | 3,065,000Source | 3,459,000Source | 4,242,000Source | 3,700,000Source | 4,070,000Source | 16,307,000Source | 12,218,000Source | 8,318,000Source |
| Dividends Payable, CurrentUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 9,797,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | -1,276,000Source | 2,578,000Source | 98,474,000Source | 37,812,000Source | -32,309,000Source | -31,805,000Source | 16,471,000Source | 12,110,000Source | 9,807,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 3,264,000Source | 3,264,000Source | 6,081,000Source | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | -1,276,000Source | 2,578,000Source | 98,474,000Source | 37,812,000Source | -32,309,000Source | -35,069,000Source | 13,207,000Source | 6,030,000Source | 9,807,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -334,000Source | 0Source | -415,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -12,034,000Source | 0Source | -11,643,000Source | 0Source | — | — | -12,034,000Source | — | — |
| GoodwillUSD | — | — | 465,140,000Source | 73,365,000Source | 470,166,000Source | 325,793,000Source | 470,169,000Source | 325,774,000Source | 470,211,000Source | 73,343,000Source | 73,354,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 7,359,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 1,518,000Source | -1,692,000Source | -2,864,000Source | -2,100,000Source | -3,086,000Source | -1,883,000Source | -5,614,000Source | -4,228,000Source | -301,000Source |
| Income Tax Expense (Benefit)USD | — | — | 276,000Source | 38,000Source | 309,000Source | 212,000Source | -62,000Source | -46,180,000Source | -51,684,000Source | 266,000Source | 288,000Source |
| Investment Income, InterestUSD | — | — | 4,600,000Source | 4,789,000Source | 3,897,000Source | 1,093,000Source | 3,866,000Source | 1,813,000Source | 12,628,000Source | 11,084,000Source | 7,601,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -79,982,000Source | -75,840,000Source | 5,642,000Source | -42,843,000Source | -125,919,000Source | -68,037,000Source | -245,028,000Source | -705,809,000Source | -214,118,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -79,982,000Source | -75,840,000Source | — | -42,843,000Source | — | -68,037,000Source | -245,028,000Source | -746,330,000Source | -265,964,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,605,000Source | -11,522,000Source | 102,757,000Source | 41,729,000Source | -27,709,000Source | -27,455,000Source | 31,447,000Source | 32,336,000Source | 21,822,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 334,206,000Source | 180,929,000Source | 382,486,000Source | 314,635,000Source | 348,116,000Source | 255,737,000Source | 1,271,789,000Source | 693,398,000Source | 531,822,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 187,891,000Source | 101,427,000Source | 225,845,000Source | 180,712,000Source | 212,594,000Source | 154,627,000Source | 731,738,000Source | 755,351,000Source | 296,760,000Source |
| Operating Income (Loss)USD | — | — | -60,996,000Source | -53,616,000Source | -75,913,000Source | -61,774,000Source | -84,711,000Source | -68,689,000Source | -252,872,000Source | -691,082,000Source | -196,083,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,605,000Source | -11,522,000Source | 102,757,000Source | 41,729,000Source | -27,709,000Source | -27,455,000Source | 31,447,000Source | 32,336,000Source | 21,822,000Source |
| Income Tax Expense (Benefit)USD | — | — | 276,000Source | 38,000Source | 309,000Source | 212,000Source | -62,000Source | -46,180,000Source | -51,684,000Source | 266,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -79,982,000Source | -75,840,000Source | 5,642,000Source | -42,843,000Source | -125,919,000Source | -68,037,000Source | -245,028,000Source | -705,809,000Source | -214,118,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.46Source | -0.46Source | 0.03Source | -0.25Source | -0.7Source | -0.4Source | -1.41Source | -6.23Source | -4.2Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.46Source | -0.46Source | 0.03Source | -0.25Source | -0.71Source | -0.4Source | -1.41Source | -6.23Source | -4.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 174,945Source | 165,612Source | 179,917Source | 173,381Source | 178,880Source | 170,506Source | 174,264Source | 119,849Source | 63,306Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 174,945Source | 165,612Source | 182,397Source | 173,381Source | 178,964Source | 170,506Source | 174,264Source | 119,849Source | 63,306Source |
| Additional Financial Items | |||||||||||
| Costs and ExpensesUSD | — | — | 395,202,000Source | 234,545,000Source | 458,399,000Source | 376,409,000Source | 432,827,000Source | 324,426,000Source | 1,524,661,000Source | 1,384,480,000Source | 727,905,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 885,000Source | 155,000Source | 165,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 3,264,000Source | 3,264,000Source | 6,081,000Source | 0Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -290,382,000Source | -701,648,000Source | -213,522,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 1,518,000Source | -1,692,000Source | -2,864,000Source | -2,100,000Source | -3,086,000Source | -1,883,000Source | -5,614,000Source | -4,228,000Source | -301,000Source |
| Interest Expense, DebtUSD | — | — | 15,399,000Source | 13,761,000Source | 10,283,000Source | 21,579,000Source | 14,341,000Source | 18,003,000Source | 70,267,000Source | 53,653,000Source | 46,869,000Source |
| Investment Income, InterestUSD | — | — | 4,600,000Source | 4,789,000Source | 3,897,000Source | 1,093,000Source | 3,866,000Source | 1,813,000Source | 12,628,000Source | 11,084,000Source | 7,601,000Source |
| Labor and Related ExpenseUSD | — | — | 72,185,000Source | 41,661,000Source | 84,147,000Source | 69,588,000Source | 79,142,000Source | 61,427,000Source | 276,208,000Source | 162,194,000Source | 135,466,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -79,982,000Source | -75,840,000Source | — | -42,843,000Source | — | -68,037,000Source | -245,028,000Source | -746,330,000Source | -265,964,000Source |
| Research and Development ExpenseUSD | — | — | 44,960,000Source | 27,348,000Source | 52,637,000Source | 41,619,000Source | 48,237,000Source | 35,874,000Source | 172,924,000Source | 149,325,000Source | 90,343,000Source |
Offerings
Registration 333-298668
Filing attachments
tem-ex99_1.htm · 8-K · 2026-11-02
Exhibit 99.1 Tempus Reports Third Quarter 2026 Results CHICAGO, November 2, 2026 - Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. “Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky…
Read attachment ↗d864810dex991.htm · S-4/A · 2026-10-20
Exhibit 99.1 PERSONALIS, INC. 6600 DUMBARTON CIRCLE FREMONT, CA 94555 SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on November 29, 2026. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction f…
Read attachment ↗d864810dex991.htm · S-4 · 2026-08-31
Exhibit 99.1 Exhibit 99.1 PRELIMINARY PROXY CARD SUBJECT TO COMPLETION SCAN TO VIEW MATERIALS & VOTE w PERSONALIS, INC. VOTE BY INTERNET 6600 DUMBARTON CIRCLE Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above FREMONT, CA 94555 Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on [•], 2026. Have your proxy card in hand when you access the website and follow the instructions to obtain your reco…
Read attachment ↗d864810dex992.htm · S-4 · 2026-08-31
Exhibit 99.2 The Board of Directors Personalis, Inc. 6600 Dumbarton Circle Fremont, CA 94555 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated July 19, 2026, to the Board of Directors of Personalis, Inc. as Annex B to, and reference to such opinion letter under the headings “Summary Term Sheet,” “Questions and Answers,” “Special Factors - Background of the Mergers,” “Special Factors - Background of the Mergers,” “Special Factors - Reasons for the Merge…
Read attachment ↗tem-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 tem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus Reports Second Quarter 2026 Results CHICAGO, July 30, 2026 - Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are…
Read attachment ↗d124162dex991.htm · 8-K · 2026-07-20
EX-99.1 2 d124162dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology with…
Read attachment ↗